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Dear Sir,  
 
Untreated, asymptomatic bacteriuria (ASB) in pregnancy is reported to be associated with 
an increased risk of pyelonephritis. Preventing pyelonephritis might prevent bloodstream 
infections (BSI) with Escherichia coli (E. coli), which could contribute to the Department of 
Health 2017 initiative to reduce Gram-negative BSI in England by 50% by 2021[1]. The NICE 
Clinical Guideline Antenatal Care for Uncomplicated Pregnancies [2], recommends offering 
routine culture-based screening for ASB during early pregnancy. However, testing practices 
for ASB in England are variable between hospitals [3].  
 
ASB screening was performed routinely at Birmingham Women’s Hospital (BWH), but it was 
identified that many patients had missed or delayed treatment. In May 2015, we 
implemented a new compulsory multidisciplinary care pathway to ensure that all women 
with true ASB detected in their booking urine were treated promptly. True ASB was defined 
as the presence of >10
5
/ml of an unequivocal uropathogen in one sample, or >10
5
/ml of an 
equivocal uropathogen in two samples. If true ASB was detected a letter was sent to the 
patient and her General Practitioner to ensure that treatment was treatment initiated 
promptly. Patients were then followed up regularly with repeat urine samples for culture for 
the rest of their pregnancies. We reviewed BSI with E. coli in maternity cases before and 
after implementation of the pathway, to determine whether this initiative has impacted the 
occurrence of BSI with E. coli in this population.  
 
The Microbiology Department maintains a prospective database of all BSI at BWH, which 
includes details on the underlying focus of the infection. Overall, the number of cases that 
were urinary tract-related has remained relatively constant throughout the observation 
period (Figure 1). However, pre-intervention 3 of the 5 urinary tract infection (UTI) related 
BSI were in antenatal women whereas, all of the 5 UTI-related BSI post-intervention were 
postnatal. The increase in overall numbers of cases of E. coli BSI in 2016-17 is difficult to 
explain. We hypothesise that the increase may have reflected an increased detection of BSI 
because of the success of sepsis awareness programmes such as the RCOG Green-top 
Guideline Bacterial Sepsis in Pregnancy. In support of this, the number of blood cultures 
(BC) received from maternity cases almost doubled from 349 in 2014-15 to 689 in 2018-19. 
A Welsh study also reported an increase in BC taken due to sepsis awareness, which 
correlated with an increase in E. coli detection [4]. The subsequent decrease in numbers of 
E. coli BSI may be because further improvement in sepsis awareness is leading to better 
recognition and treatment of early signs of infection thereby avoiding BSI.  
 
Analysis also indicated the number of early onset neonatal E. coli BSI has remained constant 
from year to year (Figure.1), suggesting that the introduction of a multidisciplinary ASB 
pathway did not impact the prevalence of early onset neonatal BSI, despite the reduction in 
antenatal UTI BSI in pregnant women.  
 
Universal screening for ASB in pregnancy has been the subject of controversy. Our study 
suggests that a multidisciplinary pathway is effective in preventing antenatal UTI related E. 
coli BSI. A recent systematic review reported that antibiotic treatment for pregnant women 
with ASB likely reduced the incidence of pyelonephritis, but the magnitude of the effect was 
uncertain. This study also reviewed screening multiple times over one-time screening, 
finding no significant evidence [5]. A previous Cochrane review concluded that routine 
screening was associated with a reduction in the incidence of pyelonephritis from 3-4% to 
0.5% [6]; however, the evidence was assessed as low quality. The UK NSC continues to 
recommend that there is insufficient information to recommend a population screening 
programme [7], which was corroborated by a 2016 systematic review [8].  
 
We do not know whether a systematic approach to ASB management has had any other 
positive or negative effects (e.g. less or more antibiotic administration, or avoidance of 
pyelonephritis without bacteraemia). However, it does not appear to be associated with 
reduction of E. coli BSI. This study is limited by the small sample size. Also, we have not 
formally assessed compliance with the protocol; however, because a midwife has allocated 
time to oversee the follow-up of women with ASB we believe that compliance is good. Large 
trials are required to determine the clinical and cost effectiveness of screening before the 
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2013-14 2014-15 2015-16 2016-17 2017-18 2018-19
Non-UTI related 3 3 3 10 4 3
UTI related 2 3 2 2 1 2
Antenatal UTI related BSI 2 1 1 0 0 0
Postnatal UTI related BSI 0 2 1 2 1 2
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Figure 1.  Numbers of cases of E. coli  Bloodstream infections (BSI) in pregnant women 
and of early onset neonatal BSI, by year. 
 
